Access to Burosumab for Patients Without Other Treatment Options
Sponsor: Kyowa Kirin Co., Ltd.
ClinicalTrials ID:NCT03775187
This program offers access to the medication Burosumab for patients who have no other available treatment options. It is available in certain countries outside the US before local approval.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
This program provides a way for patients who have no other treatment options to access Burosumab, a medication that may not yet be approved in their country. This access is available in some countries outside the United States before the medication receives local regulatory approval. For more information, please refer to the provided links.
Description
The expanded access program for Burosumab is designed to help patients who have exhausted all other treatment options. This program allows patients in certain countries outside the US to access Burosumab before it is officially approved by local health authorities. Patients interested in this program should consult the provided links for detailed information on how to apply and the specific conditions under which Burosumab can be accessed.
Eligibility Criteria
Inclusion Criteria
Exclusion Criteria
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.